PMID- 34430062
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231107
IS  - 2150-0878 (Print)
IS  - 2150-0886 (Electronic)
IS  - 2150-0878 (Linking)
VI  - 12
IP  - 5
DP  - 2021 Jul
TI  - Management of Adverse Events Associated With Tyrosine Kinase Inhibitor Use in 
      Adult Patients With Chronic Myeloid Leukemia in Chronic Phase: An Advanced 
      Practice Perspective.
PG  - 521-533
LID - 10.6004/jadpro.2021.12.5.7 [doi]
AB  - The tyrosine kinase inhibitors (TKIs) imatinib, dasatinib, nilotinib, bosutinib, 
      and ponatinib have drastically improved the life expectancies of patients with 
      chronic myeloid leukemia in chronic phase (CML-CP). While survival outcomes are 
      comparable across first-line TKIs, each TKI has a unique toxicity profile that 
      should be considered before starting or managing any treatment. Furthermore, the 
      safety and tolerability of TKIs are particularly important in CML-CP, as the 
      majority of patients remain on treatment for several years or for life. 
      Management of adverse events (AEs) is critical to ensure adherence to treatment 
      and to maintain efficacy and quality of life; management should also be 
      considered in the context of the patient's molecular response to therapy to avoid 
      switching TKIs unnecessarily. We present case studies examining pleural effusion 
      occurring with bosutinib and dasatinib, cardiovascular events associated with 
      nilotinib and ponatinib, and myelosuppression, which is common across all TKIs. 
      We discuss the management of these AEs based on international guidelines and 
      present our collective experience for advanced practitioners to consider.
CI  - (c) 2021 Harborside.
FAU - Bauer, Stephanie
AU  - Bauer S
AD  - Washington University School of Medicine in St. Louis, St. Louis, Missouri.
FAU - Comer, Holly
AU  - Comer H
AD  - Washington University School of Medicine in St. Louis, St. Louis, Missouri.
FAU - Ramsey, Brooke
AU  - Ramsey B
AD  - Washington University School of Medicine in St. Louis, St. Louis, Missouri.
FAU - Thomas, Katy
AU  - Thomas K
AD  - Washington University School of Medicine in St. Louis, St. Louis, Missouri.
LA  - eng
PT  - Journal Article
DEP - 20210701
PL  - United States
TA  - J Adv Pract Oncol
JT  - Journal of the advanced practitioner in oncology
JID - 101550346
PMC - PMC8299797
COIS- Bristol-Myers Squibb Company developed the concept of this article and reviewed a 
      draft for medical accuracy.
EDAT- 2021/08/26 06:00
MHDA- 2021/08/26 06:01
PMCR- 2021/07/01
CRDT- 2021/08/25 06:24
PHST- 2021/08/25 06:24 [entrez]
PHST- 2021/08/26 06:00 [pubmed]
PHST- 2021/08/26 06:01 [medline]
PHST- 2021/07/01 00:00 [pmc-release]
AID - 2021.12.5.7 [pii]
AID - 10.6004/jadpro.2021.12.5.7 [doi]
PST - ppublish
SO  - J Adv Pract Oncol. 2021 Jul;12(5):521-533. doi: 10.6004/jadpro.2021.12.5.7. Epub 
      2021 Jul 1.